加巴噴丁市場－全球產業規模、佔有率、趨勢、機會和預測，按劑型、類型、應用、配銷通路、地區和競爭格局分類，2020-2030年預測

2024年全球加巴噴丁市場規模為20.4億美元，預計2030年將以5.60%的複合年成長率成長至28.3億美元。加巴噴丁是一種抗驚厥藥物，主要用於治療神經性疼痛，並作為癲癇局部性發作的輔助治療藥物。慢性神經系統疾病（如癲癇和各種形式的神經性疼痛）盛行率的不斷上升，以及老年人口的成長（老年人更容易患上這些疾病），是推動全球加巴噴丁市場成長的主要因素。

主要市場促進因素

神經性疼痛疾病的日益普遍顯著推動了全球加巴噴丁市場的發展，因為該藥物是治療此類疾病的主要選擇之一。神經性疼痛是由神經損傷或疾病引起的，通常表現為慢性且令人痛苦的疼痛，因此需要有效的藥物介入。

主要市場挑戰

針對加巴噴丁潛在的誤用、濫用和超適應症用藥風險，監管機構日益嚴格的審查給全球市場帶來了重大挑戰。這種監管力度的加強促使多個司法管轄區實施更嚴格的監測方案，或將加巴噴丁重新歸類為管製藥物，這直接影響了其可近性和處方率。

主要市場趨勢

緩釋製劑的進步是影響全球加巴噴丁市場的重要因素，這主要得益於製藥業致力於提高病患依從性和治療效果。這些創新製劑的優點在於減少了給藥頻率，這對於治療神經性疼痛等慢性疾病的患者至關重要，有助於提高患者的用藥依從性，並更穩定地控制症狀。

目錄

第1章：產品概述

第2章：研究方法

第3章：執行概要

第4章：顧客之聲

第5章：全球加巴噴丁市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 按劑型（錠劑、膠囊、口服溶液）
  • 按類型（通用名、品牌名）
  • 按配銷通路（醫院藥房、零售藥房、網路藥房）
  • 依適應症（癲癇、神經性疼痛、不寧腿症候群、其他）
  • 按地區
  • 按公司（2024 年）
• 市場地圖

第6章：北美加巴噴丁市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國家分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲加巴噴丁市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國家分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區加巴噴丁市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲加巴噴丁市場展望

• 市場規模及預測
• 市佔率及預測
• 中東和非洲：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美加巴噴丁市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國家分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章：市場動態

• 促進要素
• 挑戰

第12章：市場趨勢與發展

• 併購
• 產品發布
• 最新進展

第13章：全球加巴噴丁市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商議價能力
• 顧客的力量
• 替代產品的威脅

第15章：競爭格局

• Zydus Pharmaceuticals, Inc.
• Glenmark Pharmaceuticals Limited
• Sun Pharmaceutical Industries Ltd.
• Ascend Laboratories, LLC
• Apotex Inc.
• Teva Pharmaceutical Industries Ltd.
• Aurobindo Pharma.
• Amneal Pharmaceuticals LLC.
• Cipla Ltd.
• BP Pharmaceuticals Laboratories Company

第16章：策略建議

第17章調查會社について,免責事項

The Global Gabapentin Market, valued at USD 2.04 Billion in 2024, is projected to experience a CAGR of 5.60% to reach USD 2.83 Billion by 2030. Gabapentin, an anticonvulsant medication, is primarily utilized for managing neuropathic pain and as an adjunct therapy for partial seizures in epilepsy. The global market for gabapentin is significantly driven by the increasing prevalence of chronic neurological conditions, such as epilepsy and various forms of neuropathic pain, alongside the expanding geriatric population, which is more susceptible to these disorders.

Key Market Drivers

The rising prevalence of neuropathic pain disorders significantly drives the global gabapentin market, as the medication is a primary treatment option for these conditions. Neuropathic pain, resulting from nerve damage or disease, often presents as chronic and debilitating, necessitating effective pharmaceutical interventions. According to a February 2024 article published in PubMed Central titled 'Shedding light on neuropathic pain: Current and emerging tools for diagnosis, screening, and quantification', the estimated prevalence of neuropathic pain in Europe is 7%-8%.

Key Market Challenges

Increasing regulatory scrutiny regarding gabapentin's potential for misuse, abuse, and off-label prescribing presents a significant challenge to the global market. This heightened oversight has prompted various jurisdictions to implement stricter monitoring protocols or reclassify gabapentin as a controlled substance, which directly affects its accessibility and prescription rates. Such reclassification introduces administrative complexities for healthcare providers and pharmacists, increasing the burden associated with prescribing and dispensing.

Key Market Trends

Advancements in Extended-Release Formulations are a significant factor shaping the global gabapentin market, driven by the pharmaceutical industry's focus on enhancing patient compliance and therapeutic outcomes. These innovative formulations offer advantages by reducing the frequency of dosing, which is crucial for individuals managing chronic conditions such as neuropathic pain, thereby promoting consistent medication adherence and more stable symptom control.

Key Market Players

• Zydus Pharmaceuticals, Inc.
• Glenmark Pharmaceuticals Limited
• Sun Pharmaceutical Industries Ltd.
• Ascend Laboratories, LLC
• Apotex Inc.
• Teva Pharmaceutical Industries Ltd.
• Aurobindo Pharma.
• Amneal Pharmaceuticals LLC.
• Cipla Ltd.
• BP Pharmaceuticals Laboratories Company

Report Scope:

In this report, the Global Gabapentin Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Gabapentin Market, By Form:

• Tablet
• Capsule
• Oral Solution

Gabapentin Market, By Type:

• Generic
• Branded

Gabapentin Market, By Distribution Channel:

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Gabapentin Market, By Application:

• Epilepsy
• Neuropathic Pain
• Restless Legs Syndrome
• Others

Gabapentin Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Gabapentin Market.

Available Customizations:

Global Gabapentin Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Gabapentin Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Form (Tablet, Capsule, Oral Solution)
  • 5.2.2. By Type (Generic, Branded)
  • 5.2.3. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
  • 5.2.4. By Application (Epilepsy, Neuropathic Pain, Restless Legs Syndrome, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2024)
• 5.3. Market Map

6. North America Gabapentin Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Form
  • 6.2.2. By Type
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Application
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Gabapentin Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Form
      • 6.3.1.2.2. By Type
      • 6.3.1.2.3. By Distribution Channel
      • 6.3.1.2.4. By Application
  • 6.3.2. Canada Gabapentin Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Form
      • 6.3.2.2.2. By Type
      • 6.3.2.2.3. By Distribution Channel
      • 6.3.2.2.4. By Application
  • 6.3.3. Mexico Gabapentin Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Form
      • 6.3.3.2.2. By Type
      • 6.3.3.2.3. By Distribution Channel
      • 6.3.3.2.4. By Application

7. Europe Gabapentin Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Form
  • 7.2.2. By Type
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Application
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Gabapentin Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Form
      • 7.3.1.2.2. By Type
      • 7.3.1.2.3. By Distribution Channel
      • 7.3.1.2.4. By Application
  • 7.3.2. France Gabapentin Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Form
      • 7.3.2.2.2. By Type
      • 7.3.2.2.3. By Distribution Channel
      • 7.3.2.2.4. By Application
  • 7.3.3. United Kingdom Gabapentin Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Form
      • 7.3.3.2.2. By Type
      • 7.3.3.2.3. By Distribution Channel
      • 7.3.3.2.4. By Application
  • 7.3.4. Italy Gabapentin Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Form
      • 7.3.4.2.2. By Type
      • 7.3.4.2.3. By Distribution Channel
      • 7.3.4.2.4. By Application
  • 7.3.5. Spain Gabapentin Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Form
      • 7.3.5.2.2. By Type
      • 7.3.5.2.3. By Distribution Channel
      • 7.3.5.2.4. By Application

8. Asia Pacific Gabapentin Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Form
  • 8.2.2. By Type
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Application
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Gabapentin Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Form
      • 8.3.1.2.2. By Type
      • 8.3.1.2.3. By Distribution Channel
      • 8.3.1.2.4. By Application
  • 8.3.2. India Gabapentin Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Form
      • 8.3.2.2.2. By Type
      • 8.3.2.2.3. By Distribution Channel
      • 8.3.2.2.4. By Application
  • 8.3.3. Japan Gabapentin Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Form
      • 8.3.3.2.2. By Type
      • 8.3.3.2.3. By Distribution Channel
      • 8.3.3.2.4. By Application
  • 8.3.4. South Korea Gabapentin Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Form
      • 8.3.4.2.2. By Type
      • 8.3.4.2.3. By Distribution Channel
      • 8.3.4.2.4. By Application
  • 8.3.5. Australia Gabapentin Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Form
      • 8.3.5.2.2. By Type
      • 8.3.5.2.3. By Distribution Channel
      • 8.3.5.2.4. By Application

9. Middle East & Africa Gabapentin Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Form
  • 9.2.2. By Type
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Application
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Gabapentin Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Form
      • 9.3.1.2.2. By Type
      • 9.3.1.2.3. By Distribution Channel
      • 9.3.1.2.4. By Application
  • 9.3.2. UAE Gabapentin Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Form
      • 9.3.2.2.2. By Type
      • 9.3.2.2.3. By Distribution Channel
      • 9.3.2.2.4. By Application
  • 9.3.3. South Africa Gabapentin Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Form
      • 9.3.3.2.2. By Type
      • 9.3.3.2.3. By Distribution Channel
      • 9.3.3.2.4. By Application

10. South America Gabapentin Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Form
  • 10.2.2. By Type
  • 10.2.3. By Distribution Channel
  • 10.2.4. By Application
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Gabapentin Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Form
      • 10.3.1.2.2. By Type
      • 10.3.1.2.3. By Distribution Channel
      • 10.3.1.2.4. By Application
  • 10.3.2. Colombia Gabapentin Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Form
      • 10.3.2.2.2. By Type
      • 10.3.2.2.3. By Distribution Channel
      • 10.3.2.2.4. By Application
  • 10.3.3. Argentina Gabapentin Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Form
      • 10.3.3.2.2. By Type
      • 10.3.3.2.3. By Distribution Channel
      • 10.3.3.2.4. By Application

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Gabapentin Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Zydus Pharmaceuticals, Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Glenmark Pharmaceuticals Limited
• 15.3. Sun Pharmaceutical Industries Ltd.
• 15.4. Ascend Laboratories, LLC
• 15.5. Apotex Inc.
• 15.6. Teva Pharmaceutical Industries Ltd.
• 15.7. Aurobindo Pharma.
• 15.8. Amneal Pharmaceuticals LLC.
• 15.9. Cipla Ltd.
• 15.10. BP Pharmaceuticals Laboratories Company

16. Strategic Recommendations

17. About Us & Disclaimer